Generics - Actavis

Filter

Current filters:

Actavis

Popular Filters

60 to 84 of 1247 results

Setting the record straight: Australia’s PBS expenditure is in decline

21-02-2014

Comments made this week by Australia’s federal Health Minister, Peter Dutton MP, about expenditure…

Asia-PacificAustraliaFinancialGenericsHealthcarePharmaceutical

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

20-02-2014

Acquisitive Ireland-headquartered generics major Actavis says that net revenue leapt 59% to $2.779 billion…

ActavisFinancialGenerics

Fitch affirms Actavis at “BBB-” on Forest Labs acquisition; outlook Stable

20-02-2014

Fitch Ratings has affirmed the ratings of generic drugs major Actavis and subsidiaries at “BBB-”…

ActavisFinancialForest LaboratoriesMergers & AcquisitionsPharmaceutical

Actavis confirms plan to acquire Forest Labs for about $25 billion

Actavis confirms plan to acquire Forest Labs for about $25 billion

18-02-2014

After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached…

ActavisForest LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

NZ’s PHARMAC tender reveals vibrant market for pharmaceuticals

NZ’s PHARMAC tender reveals vibrant market for pharmaceuticals

12-02-2014

The number of companies bidding to be suppliers through PHARMAC, New Zealand’s Pharmaceutical Management…

Asia-PacificGenericsHealthcarePricing

Dr Reddy’s sees generics soar due to limited competition

Dr Reddy’s sees generics soar due to limited competition

11-02-2014

India’s second-largest drugmaker Dr Reddy's Laboratories has reported strong third quarter sales of…

Dr Reddy's LaboratoriesFinancialGenericsIndiaPharmaceutical

Cadila net profit up by 82% in third-quarter

07-02-2014

Indian drugmaker Cadila Healthcare posted a net profit of 1.86 billion rupees ($29.7 million), for the…

BiosimilarsCadila PharmaceuticalsFinancialGenericsResearchZydus Cadila

Teva’s full year results steady led by Copaxone sales up 8%

Teva’s full year results steady led by Copaxone sales up 8%

07-02-2014

Israel-based Teva Pharmaceutical Industries has released its full year results for 2014 showing that…

CopaxoneEastern EuropeFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

New data shows FDA’s proposed generic labeling rules would add to health costs

New data shows FDA’s proposed generic labeling rules would add to health costs

06-02-2014

The US Food and Drug Administration’s Proposed Rule on prescription drug labeling would add $4 billion…

FinancialGenericsNorth AmericaRegulationUSA

Ranbaxy rises on 4th-qtr performance, but can this continue?

Ranbaxy rises on 4th-qtr performance, but can this continue?

05-02-2014

Ranbaxy Laboratories, India’s largest generic drugmaker by sales, saw its shares rise 5.6% to 340 rupees…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Spain continues reduction of pharma spending and starts adopting value based pricing

04-02-2014

The Spanish Ministry of Health last week announced pharmaceutical spending data, which showed a new drop…

EuropeFinancialGenericsHealthcarePharmaceuticalPricingSpain

US health advocacy groups state case on biosimilars naming policy

04-02-2014

In advance of today's US Federal Trade Commission workshop on follow-on biologics, or biosimilars, health…

BiosimilarsGenericsNorth AmericaRegulationUSA

Actavis confirms generic Treanda patent challenge

Actavis confirms generic Treanda patent challenge

04-02-2014

US generics drug major Actavis confirms that it has filed an Abbreviated New Drug Application with the…

ActavisCephalonGenericsNorth AmericaOncologyPatentsTeva Pharmaceutical IndustriesTreandaUSA

US generics lobby group, GPhA, sets out 2014 priorities

US generics lobby group, GPhA, sets out 2014 priorities

04-02-2014

The US trade group the Generic Pharmaceutical Association (GPhA) has identified its key priorities for…

BiosimilarsGenericsHealthcareNorth AmericaRegulationUSA

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Actavis refocuses global business structure; reiterates 2014 outlook

Actavis refocuses global business structure; reiterates 2014 outlook

01-02-2014

US generics major Actavis, which now has its headquarters in Ireland, has announced a realignment of…

ActavisBoardroomFinancialGenerics

US Congressmen express concerns on FDA’s proposed change to generic drug labeling policy

US Congressmen express concerns on FDA’s proposed change to generic drug labeling policy

30-01-2014

US Senator Lamar Alexander (Republican, Tennessee), the senior Republican on the Senate Health Committee,…

GenericsNorth AmericaPoliticsRegulationUSA

Call for strategic regulatory rethink for EU generic medicines industry

Call for strategic regulatory rethink for EU generic medicines industry

27-01-2014

“It is vital that costs associated with regulatory processes do not become a barrier to developing…

EuropeFinancialGenericsRegulation

Actavis to shed another business, its Actavis Foshan unit in China

Actavis to shed another business, its Actavis Foshan unit in China

26-01-2014

US generics major Actavis revealed a second divestiture this month, saying it has signed and completed…

ActavisAsia-PacificChinaGenericsMergers & AcquisitionsZhejiang Chiral

Another ban by US FDA on a Ranbaxy production facility

Another ban by US FDA on a Ranbaxy production facility

24-01-2014

As if the Indian drug major has not had enough negative news from the US regulator, the US Food and Drug…

Asia-PacificDaiichi SankyoGenericsIndiaNorth AmericaProductionRanbaxy LaboratoriesRegulationUSA

60 to 84 of 1247 results

Back to top